On May 18, 2026, Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a leading player in radiopharmaceutical development, announced a significant milestone in its ongoing clinical research. The company confirmed that the first patients have been dosed in two new cohorts of its Phase 1/2a studies, involving the promising compounds [212Pb]VMT-α-NET and [212Pb]PSV359, which target various forms of cancer.

1. Pioneering Advances in Neuroendocrine Tumors

In the first trial, the initial patient treated with [212Pb]VMT-α-NET is part of a fourth cohort aimed at patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs). The study is designed to optimize a cumulative dose of 20 mCi through a front-loading regimen. This innovative dosing schedule includes:

First Dose: 6.0 mCi

Second Dose: 5.0 mCi

Third Dose: 5.0 mCi

Fourth Dose: 4.0 mCi

The goal is to evaluate how this front-loading approach might enhance response kinetics and improve both response rates and tolerability, all while delivering the same cumulative dose.

2. Innovative Approach to Solid Tumors

Simultaneously, the company has initiated dosing in a third cohort of its Phase 1/2a trial for [212Pb]PSV359. This trial focuses on the safety and preliminary anti-tumor activity of the radiopharmaceutical in patients with solid tumors expressing fibroblast activation protein alpha (FAP-α).

Following a rigorous safety review by the monitoring committee, Cohort 3 was cleared to begin, allowing patients to receive up to four fixed doses of 6.0 mCi administered every eight weeks.

3. The Science Behind [212Pb]VMT-α-NET and PSV359

Effective Targeting with [212Pb]VMT-α-NET

[212Pb]VMT-α-NET is developed to selectively deliver the alpha-emitting isotope 212Pb to tumors expressing SSTR2. The clinical study is a multi-center, open-label, dose-escalation, and dose-expansion trial (NCT05636618) targeting patients who have not previously undergone radiopharmaceutical therapies. Interim efficacy data, presented at the American Association for Cancer Research Annual Meeting 2026, showcased promising results for half of the patients in Cohort 2, with additional data pending.

Advancements with PSV359

Similarly, PSV359 is engineered to bind to tumors expressing FAP-α, a target associated with several prevalent solid tumors. The innovative design of PSV359 allows for potential imaging capabilities with alternative isotopes like 203Pb or 68Ga (known as PSV377), which can help assess FAP-α expression. Perspective Therapeutics aims to determine the recommended Phase 2 dose of PSV359 through its ongoing multi-center study (NCT06710756) while also evaluating anti-tumor activity as a primary outcome measure.

4. Commitment to Cancer Treatment Innovation

Perspective Therapeutics is at the forefront of radiopharmaceutical innovation, utilizing its proprietary technology to deliver targeted therapies that maximize treatment efficacy while minimizing toxicity. The company is expanding its clinical-stage programs, which now include VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma, and PSV359 for solid tumors.

In addition, Perspective is enhancing its regional supply network for finished drug products through its proprietary 224Ra/212Pb generator platform, ensuring a robust pipeline for clinical trials and potential commercialization.

As Perspective Therapeutics continues to make strides in clinical research, the biopharmaceutical industry watches closely for further developments in these promising therapies that could redefine cancer treatment paradigms.

Original press release